A dual time window-driven strategy to optimize primary biliary cholangitis treatment via alkaline phosphatase normalization
image: ALP normalization significantly improves clinical outcomes. Two subgroups demonstrate low normalization probability and warrant early intervention: (1) patients with ALP ≥ 1.67 × ULN after 3 months and (2) those not meeting Paris II criteria by month 6.
Credit: Ying Han, Yulong Shang
Background and Aims
The current criterion of biochemical response to ursodeoxycholic acid in primary biliary cholangitis is an alkaline phosphatase (ALP) level of ≤1.67 × the upper limit of normal (ULN) after 12 months of treatment. However, a proportion of patients who meet this parameter may still progress to liver decompensation. This study aimed to optimize the clinical management of primary biliary cholangitis by (1) establishing ALP normalization as a core treatment target, (2) identifying early intervention windows, and (3) developing risk stratification criteria.
Methods
This multicenter retrospective study included an internal cohort and an external validation cohort. We assessed the prognostic impact of ALP normalization with Kaplan-Meier and Cox regression. Sankey diagrams and segmented Poisson regression analysis mapped dynamic risk transitions to identify critical intervention windows. Predictive performance (sensitivity/specificity/positive predictive value/negative predictive value [NPV]) of Mayo, Paris II, and Toronto criteria for 12-month ALP normalization was compared.
Results
Patients achieving ALP normalization showed significantly higher complication-free survival versus those with ALP 1.0–1.67 × ULN (89.8% vs. 79.8%; P = 0.016). Segmented Poisson regression identified significant change points at 3.73 and 5.5 months for high-to-medium and medium-to-low risk transitions, respectively. Failure to meet the Toronto criteria at month 3 predicted non-normalization with 95% NPV, whereas Paris II criteria at month 6 provided optimal specificity (73%) for identifying patients who failed to achieve ALP normalization.
Conclusions
This study establishes ALP normalization (≤1.0 × ULN) as a superior therapeutic target in PBC, demonstrating a 10.0 percentage-point improvement in complication-free survival (89.8% vs. 79.8% at median follow-up) compared with patients maintaining ALP levels between 1.0 and 1.67 × ULN. These findings indicate that current biochemical response criteria may inadequately stratify risk, as a substantial proportion of patients classified as “responders” remain at elevated risk for adverse outcomes.
Our longitudinal analysis identified two critical intervention windows for treatment intensification. At 3 months, patients with ALP ≥ 1.67 × ULN show markedly reduced normalization probability (NPV 95% by Toronto criteria), warranting early consideration of second-line therapies. At 6 months, failure to meet Paris II criteria reliably identifies patients unlikely to achieve normalization (specificity 73%). This dual time window–driven strategy enables timely intervention while avoiding premature treatment escalation.
The clinical implications are threefold: treatment goals should prioritize complete ALP normalization; biochemical monitoring at 3 and 6 months provides actionable decision points for therapy intensification; and older patients (>50 years) warrant enhanced surveillance despite meeting conventional response criteria. While prospective validation is needed, this time window–based framework offers a practical approach to implementing precision medicine in PBC management, potentially reducing liver-related complications and improving long-term outcomes.
Full text
https://www.xiahepublishing.com/2310-8819/JCTH-2026-00082
The study was recently published in the Journal of Clinical and Translational Hepatology.
The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study’s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.
Follow us on X: @xiahepublishing
Follow us on LinkedIn: Xia & He Publishing Inc.